Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 13/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896712 | 0.81 | KCNN4 (0.40) | KCNN4NOTUMNPC1RAB9ALMNA | |
| SCHEMBL2657250 | 0.81 | KCNN4 (0.42) | KCNN4NOTUMNPC1RAB9ALMNA | |
| SCHEMBL2897051 | 0.80 | KCNN4 (0.36) | KCNN4NOTUMNPC1RAB9ALMNA | |
| SCHEMBL19527731 | 0.77 | NOTUM (0.38) | KCNN4NOTUMNPC1RAB9ALMNA | |
| SCHEMBL5545479 | 0.76 | KCNN4 (0.60) | KCNN4 | |
| SCHEMBL5222424 | 0.76 | KCNN4 (0.35) | KCNN4NOTUMNPC1RAB9ALMNA | |
| SCHEMBL15337292 | 0.75 | KCNN4 (0.36) | KCNN4NOTUMLMNA | |
| SCHEMBL15337360 | 0.73 | NOTUM (0.43) | KCNN4NOTUMLMNASMN1; SMN2 | |
| SCHEMBL13408564 | 0.72 | L3MBTL1 (0.42) | KCNN4NPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL1486496 | 0.72 | CA12 (0.54) | ESR1ESR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212939-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-01 | — | — | US | disclosed |
| CN-102131778-A | Heterocyclic gpcr agonists | PROSIDION LTD | 2011-07-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212939-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GPR27 | ESR1 419/4885ESR2 390/4885KCNN4 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.